Sacubitril/Valsartan and Cardiac Remodeling in Hypotensive HFrEF

Поділитися
Вставка
  • Опубліковано 2 чер 2024
  • Dr. Chien-Yi Hsu, an Associate Professor in Cardiology at Taipei Medical University Hospital, in Taipei, Taiwan, reviews his article appearing in the June 2024 issue of Mayo Clinic Proceedings, where he investigated whether hypotensive patients diagnosed with heart failure and reduced ejection fraction (HFrEF) might benefit from angiotensin receptor-neprilysin inhibitors - ARNis - in real-world practice. Dr. Hsu recommends HFrEF patients with hypotension may still benefit from ARNi treatment and should not be routinely excluded from ARNi use. Available at: mayocl.in/44ooEQK
  • Наука та технологія

КОМЕНТАРІ •